PDCD1 and metastatic melanoma: The first immune checkpoint association with anti-PD-1 and CTLA-4 antibodies was in 2009 [87]; a response rate of 60% in patients with metastatic melanoma in phase II and phase III trials was observed, with respect to anti-PD-1 PD-1 blockade alone.